Edgewise Therapeutics (NASDAQ:EWTX – Get Rating) issued its quarterly earnings results on Wednesday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.02), MarketWatch Earnings reports.
Shares of Edgewise Therapeutics stock opened at $7.47 on Friday. The firm’s 50 day simple moving average is $9.30 and its two-hundred day simple moving average is $13.83. Edgewise Therapeutics has a 12-month low of $6.93 and a 12-month high of $29.98.
Several large investors have recently bought and sold shares of the company. BlackRock Inc. raised its stake in Edgewise Therapeutics by 252.9% in the 4th quarter. BlackRock Inc. now owns 2,047,603 shares of the company’s stock worth $31,288,000 after acquiring an additional 1,467,371 shares during the last quarter. State Street Corp raised its stake in shares of Edgewise Therapeutics by 165.5% in the fourth quarter. State Street Corp now owns 528,638 shares of the company’s stock worth $8,078,000 after purchasing an additional 329,542 shares during the last quarter. Norges Bank acquired a new stake in shares of Edgewise Therapeutics during the fourth quarter worth about $4,610,000. Geode Capital Management LLC boosted its position in Edgewise Therapeutics by 61.2% in the fourth quarter. Geode Capital Management LLC now owns 391,582 shares of the company’s stock valued at $5,983,000 after buying an additional 148,663 shares during the last quarter. Finally, Nuveen Asset Management LLC increased its holdings in Edgewise Therapeutics by 222.3% in the 4th quarter. Nuveen Asset Management LLC now owns 93,350 shares of the company’s stock worth $1,801,000 after buying an additional 64,387 shares during the period.
About Edgewise Therapeutics (Get Rating)
Edgewise Therapeutics, Inc, a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial.
- Get a free copy of the StockNews.com research report on Edgewise Therapeutics (EWTX)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.